Results 201 to 210 of about 18,821 (231)

Biology and Pharmacology of the Platelet P2Y12 Receptor

Current Pharmaceutical Design, 2006
Platelets possess two receptors for ADP, P2Y(1) and P2Y(12). ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y(1) receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.
openaire   +2 more sources

Microglia modulate general anesthesia through P2Y12 receptor

Current Biology, 2023
General anesthesia (GA) is an unconscious state produced by anesthetic drugs, which act on neurons to cause overall suppression of neuronal activity in the brain. Recent studies have revealed that GA also substantially enhances the dynamics of microglia, the primary brain immune cells, with increased process motility and territory surveillance. However,
Kelei Cao, Liyao Qiu, Xuan Lu, Weiying Wu, Yaling Hu, Zhicheng Cui, Chao Jiang, Yuxiang Luo, Yujin Shao, Wang Xi, Ling-Hui Zeng, Han Xu, Huan Ma, Zhi Zhang, Jiyun Peng, Shumin Duan, Zhihua Gao   +16 more
openaire   +2 more sources

P2Y12 receptor: platelet thrombus formation and medical interventions

International Journal of Hematology, 2012
Platelets express a wide range of receptors and proteins that play essential roles in thrombus formation. Among these, the P2Y(12) receptor, a member of the G protein-coupled receptor family, has attracted a significant amount of attention. Stimulation of the P2Y(12) receptor by ADP results in activation of various signaling pathways involved in ...
Fatemeh Moheimani, Denise E Jackson
exaly   +4 more sources

Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

Clinical Pharmacokinetics, 2020
Coronary artery disease remains the major cause of mortality worldwide. Antiplatelet drugs such as acetylsalicylic acid and P2Y12 receptor antagonists are cornerstone treatments for the prevention of thrombotic events in patients with coronary artery disease.
Uta Schilling, Jasper Dingemanse, Mike Ufer   +2 more
openaire   +2 more sources

Switching Platelet P2Y12 Receptor Inhibiting Therapies

Interventional Cardiology Clinics
Antiplatelet therapy involving aspirin and a P2Y12 receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y12 inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns.
Luis, Ortega-Paz, Fabiana, Rollini, Francesco, Franchi, Dirk, Sibbing, Dominick J, Angiolillo   +4 more
openaire   +2 more sources

Decreased platelet inhibition by P2Y12 receptor blockers in anaemia

European Journal of Clinical Investigation, 2017
AbstractBackgroundAnaemic patients undergoing angioplasty and stenting are at an increased risk of ischaemic events, which may be caused by an inadequate response to antiplatelet therapy with adenosine diphosphate (ADP) P2Y12 inhibitors. In the current study, we investigated the associations between anaemia and on‐treatment platelet reactivity in ...
Patricia P. Wadowski, Christoph W. Kopp, Renate Koppensteiner, Irene M. Lang, Joseph Pultar, Silvia Lee, Constantin Weikert, Simon Panzer, Thomas Gremmel   +8 more
openaire   +2 more sources

P2Y12 receptor residues crucial for thrombosis regulation

Journal of Molecular Recognition, 2023
AbstractThrombosis, or the formation of blood clots, can lead to serious medical conditions such as stroke, heart attack, and deep vein thrombosis. The purinoreceptor P2Y12 plays a critical role in the thrombotic pathway and is targeted for therapy to prevent clot formation.
openaire   +2 more sources

The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin

Cellular and Molecular Life Sciences, 2018
Atherosclerosis is a chronic and progressive disease of the arterial walls and a leading cause of non-cardioembolic ischemic stroke. P2Y12 is a well-recognized receptor that is expressed on platelets and is a target of thienopyridine-type antiplatelet drugs.
Ying, Gao, Cheng, Yu, Shulan, Pi, Ling, Mao, Bo, Hu   +4 more
openaire   +2 more sources

Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist

Annals of Pharmacotherapy, 2010
Objective: To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS).
Benjamin J Epstein
exaly   +3 more sources

The P2Y12 receptor regulates microglial activation by extracellular nucleotides

Nature Neuroscience, 2006
Microglia are primary immune sentinels of the CNS. Following injury, these cells migrate or extend processes toward sites of tissue damage. CNS injury is accompanied by release of nucleotides, serving as signals for microglial activation or chemotaxis. Microglia express several purinoceptors, including a G(i)-coupled subtype that has been implicated in
Sharon E, Haynes, Gunther, Hollopeter, Guang, Yang, Dana, Kurpius, Michael E, Dailey, Wen-Biao, Gan, David, Julius   +6 more
openaire   +2 more sources